Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), Victoria de Giorgio‐Miller(AstraZeneca (United Kingdom)), Sara Y. Brucker(University Children's Hospital Tübingen), Gareth D. James, Joohyuk Sohn(Yonsei University), D. Varghese(AstraZeneca (United States)), Abel Livingston(AstraZeneca (United Kingdom)), Adam Brufsky(University of Pittsburgh), Mark Basik(Jewish General Hospital), Frédérique Penault‐Llorca(Inserm), Gavin C. Higgins(Victorian Cancer Biobank), Rita Sousa(Hospital de Santa Maria), Carl O’brien(The Christie NHS Foundation Trust), Naoki Hayashi(St. Luke's International Hospital), Fernando Schmitt(Universidade do Porto), Eriko Tokunaga(National Hospital Organization Kyushu Cancer Center), Angela Moh(Daiichi Sankyo (United States)), Naoki Niikura(Tokai University)
Cited by 76
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k